What are my options for treating follicular lymphoma?

Yeah, the treatment options for follicular lymphoma vary depending on the stage and characteristics of the disease. In the frontline setting, options range from observation to more active treatments. For patients with localized follicular lymphoma, radiation therapy may be an option, potentially leading to long-term remissions. However, when the disease has spread to other areas, such as above and below the diaphragm or into the bone marrow, treatment options expand.

These options include observation, rituximab as a single agent, or chemotherapy regimens such as bendamustine with rituximab or R-CHOP. In the relapsed or refractory setting, there's no standard therapy, and treatment depends on the specific situation. For patients who relapse within 24 months, CAR-T cell therapy might be considered, along with other options like lenalidomide with rituximab.

For initial therapy, the traditional approach often involves observing patients until they show a high burden of disease, such as significantly swollen lymph nodes or organ involvement. We use criteria like the GELF criteria to measure the extent of the disease. Once treatment is necessary, it's usually a combination of immunotherapy and chemotherapy. The most commonly used immunotherapies are monoclonal antibodies like rituximab or Obinutuzumab, often paired with bendamustine, which is well-tolerated and effective in treating follicular lymphoma.

There are situations where rituximab might be used alone, particularly if chemotherapy isn't well-tolerated. Excitingly, clinical trials are exploring chemotherapy-free approaches, which may offer patients a more tolerable treatment option with long remissions and potentially fewer side effects.